Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome

Poruba, Martin; Kazdová, Ludmila; Oliyarnyk, Olena; Malínská, Hana; Matušková, Zuzana; Angelo, Igor Tozzi Di; Škop, Vojtěch; Večeřa, Rostislav

doi:10.3109/00498254.2015.1010633

Cited by 24 publications

(30 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cholesterol-lowering effect (-16 % or -18 %; p<0.01) was measured in group supplemented with n-3 PUFA without or with SM, respectively, compared to the controls. The hypolipidemic effects of SM are consistent with our earlier findings showing its effects on the reduction of serum TAG concentrations in HHTg rats and dietary-induced hypercholesterolemia (Orolin et al 2007, Poruba et al 2015. We did not test this effect of SM alone again.…”

Section: Parameters Of Antioxidant System and Lipoperoxidationsupporting

confidence: 89%

See 1 more Smart Citation

The Effect of Combined Diet Containing n-3 Polyunsaturated Fatty Acids and Silymarin on Metabolic Syndrome in Rats

Poruba¹,

Anzenbacher²,

Rácová

et al. 2019

Physiol Res

View full text Add to dashboard Cite

The risk of development of metabolic syndrome can be increased by hypertriglyceridemia. A search for effective therapy is a subject of considerable attention. Therefore, our hypothesis is that the fish oil (containing polyunsaturated fatty acids; n-3 PUFA) in a combination with silymarin can more effectively protect against hypertriglyceridemia-induced metabolic disturbances. The study was conducted using a unique non-obese strain of rats with hereditary hypertriglyceridemia an accepted model of metabolic syndrome. Adult male rats were treated with n-3 PUFA (300 mg/kg/day) without or with 1 % micronized silymarin in a diet for 4 weeks. The treatment with the diet containing n-3 PUFA and silymarin significantly reduced concentrations of serum triglycerides (-45 %), total cholesterol (-18 %), non-esterified fatty acids (-33 %), and ectopic lipid accumulation in skeletal muscle (-35 %) compared to controls. In addition, an increase in Abcg5 and Abcg8 mRNA expression (as genes affecting lipid homeostasis) as well as in protein content of ABCG5 (+78 %) and ABCG8 (+232 %) transporters have been determined in the liver of treated rats. Our findings suggest that this combined diet could be used in the prevention of hypertriglyceridemia-induced metabolic disorders.

show abstract

Section: Parameters Of Antioxidant System and Lipoperoxidationsupporting

confidence: 89%

“…Additionally, hypolipidemic and glucose-lowering properties of SM have been observed as well Krecman 1998, Skottova et al 2003). Recently, it was found that the micronized form of SM provides more pronounced effects than standardized extract, mainly due to its better solubility (Zhang et al 2009, Poruba et al 2015).…”

Section: Introductionmentioning

confidence: 99%

The Effect of Combined Diet Containing n-3 Polyunsaturated Fatty Acids and Silymarin on Metabolic Syndrome in Rats

Poruba¹,

Anzenbacher²,

Rácová

et al. 2019

Physiol Res

View full text Add to dashboard Cite

show abstract

Section: Studies On Silymarinmentioning

confidence: 61%

“…In this study, silymarin increased HDL level, which has an important role in the reverse transport of cholesterol. This study also showed that phytosome and micronized forms of silymarin were the most effective forms because of their better bioavailability (Poruba et al, ). Moreover, administration of silymarin and polyphenolic fraction of silymarin significantly decreased cholesterol absorption, the plasma level of cholesterol, liver content of VLDL, and triacylglycerol.…”

Section: Effect On Lipid Profilementioning

confidence: 87%

“…Also, it is suggested that silybin probably blocks the interaction between endothelial cells and circulating monocytes by inhibiting TNF‐α‐induced expression of endothelial cell adhesion molecules intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 (Wallace et al, ). Moreover, silymarin can increase HDL level, which has a protective effect on atherosclerosis and an important role in the reverse transport of cholesterol (Poruba et al, ). In another study, silybin markedly improves endothelial dysfunction in mice by reducing circulating and vascular dimethylarginine levels.…”

Section: Cardiovascular Protective Effectmentioning

confidence: 99%

See 1 more Smart Citation

Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review

Tajmohammadi

Razavi

Hosseinzadeh

2018

Phytotherapy Research

View full text Add to dashboard Cite

Metabolic syndrome describes a complex metabolic risk factors including obesity, hypertension, dyslipidemia, and diabetes. This syndrome is diagnosed by medical conditions such as weight gain, high blood pressure, high blood glucose, and disturbance in lipid profile. Metabolic syndrome has become as an important and increasing global health problem, so finding potentially novel solutions with less adverse effects is favorable for health problems. Herbal therapy plays an important role for treatment of different diseases. Silybum marianum is a plant that is used for centuries as a herbal treatment in liver and biliary tract diseases. Silymarin is the main component of S. marianum and derived from fruits and seeds of S. marianum (milk thistle). S. marianum has been found to exhibit antioxidant, lipid-lowering, antihypertensive, antidiabetic, antiatherosclerotic, anti-obesity, and hepatoprotective effects. Therefore, the aim of this review is to summarize different animal and human studies regarding the effect of S. marianum in metabolic syndrome and to identify the underlying mechanisms of action.

show abstract

Effect of Silymarin Treatment on Circulating Bilirubin and Cardiovascular Disease Risk Factors in Healthy Men: A Single‐Blind, Randomized Crossover Trial

Vidimce

Pennell

Foo

et al. 2021

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

This clinical trial (ACTRN12619001296123) investigated the impact of silymarin (Legalon®) on circulating bilirubin concentration, lipid status, systemic inflammation, and antioxidant status. The study design was a randomized, placebo‐controlled, single‐blind crossover trial of healthy men (18‐65 years), conducted at Griffith University, Gold Coast, Australia. Participants were recruited from Griffith University and were randomized to silymarin (140 mg silymarin capsules thrice daily) or placebo (3 capsules containing mannitol taken daily) for 14 days followed by a ≥4‐week washout and crossover to the other arm. The main outcomes were whether silymarin treatment would increase serum bilirubin concentration by >0.29 mg/dL, change serum lipid status (cholesterol and triglycerides), inflammation (c‐reactive protein), and antioxidant capacity (ferric reducing ability of plasma) compared with baseline. Silymarin consumption (n = 17) did not affect serum concentrations of unconjugated bilirubin (0.73 versus 0.67 mg/dL, P = .79), cholesterol (185 versus 189 mg/dL, P = .19), triglycerides (94.2 versus 92.3 mg/dL, P = .79), c‐reactive protein (0.17 versus 0.09 mg/dL, P = .23), or antioxidant status (6.61 versus 6.67 mg Fe2+/dL, P = .40). These findings challenge previous reports and manufacturer claims of hyperbilirubinemia following silymarin treatment and are critical to guiding researchers toward an effective means to mildly elevate bilirubin, which evidence suggests could protect from cardiovascular disease.

show abstract

Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome

Cited by 24 publications

References 35 publications

The Effect of Combined Diet Containing n-3 Polyunsaturated Fatty Acids and Silymarin on Metabolic Syndrome in Rats

The Effect of Combined Diet Containing n-3 Polyunsaturated Fatty Acids and Silymarin on Metabolic Syndrome in Rats

Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review

Effect of Silymarin Treatment on Circulating Bilirubin and Cardiovascular Disease Risk Factors in Healthy Men: A Single‐Blind, Randomized Crossover Trial

Contact Info

Product

Resources

About